Physician profile
Edward V Hebert
NPI 1982783312
$5,069.69
in general payments reported to CMS, 2019-2025
37 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $265 · 2021: $703 · 2022: $501 · 2023: $611 · 2024: $1,573 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992 · Travel and Lodging: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.14 |
| Travel and Lodging | $753.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $1,000.53 | 2024 | Varian Ethos Treatment Planning, Truebeam |
| Abbvie INC. | $575.19 | 2019-2025 | |
| Pfizer INC. | $512.06 | 2019-2025 | |
| Novo Nordisk INC | $490.70 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Glaxosmithkline, LLC. | $443.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $287.73 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Sumitomo Pharma America, INC. | $164.08 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $142.91 | 2019-2025 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $138.21 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.85 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $107.11 | 2019-2022 | |
| Amarin Pharma, INC. | $90.62 | 2019-2021 | |
| Exact Sciences Corporation | $89.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $82.32 | 2021-2024 | |
| Esperion Therapeutics, INC. | $76.43 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $75.89 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Amgen INC. | $74.40 | 2019-2025 | Prolia, Evenity, Otezla |
| Sanofi-Aventis U.S. LLC | $70.67 | 2019-2020 | |
| Ardelyx, INC. | $69.12 | 2024-2025 | Ibsrela |
| Dexcom, INC. | $56.06 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.86 | 2019-2021 | |
| Allergan, INC. | $37.79 | 2019 | |
| Antares Pharma, INC. | $37.18 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $36.06 | 2021 | |
| Phathom Pharmaceuticals, INC. | $30.78 | 2023-2025 | Voquezna |
| Arbor Pharmaceuticals, INC. | $27.34 | 2021 | |
| Insulet Corporation | $24.45 | 2024 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $23.92 | 2022 | |
| Avanir Pharmaceuticals, INC. | $22.18 | 2022 | |
| Biogen, INC. | $20.17 | 2021 | |
| Alfasigma USA, INC. | $19.76 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.37 | 2024 | Quviviq |
| Daiichi Sankyo INC. | $16.29 | 2019 | |
| Eisai INC. | $14.75 | 2021 | |
| Philips North America LLC | $14.46 | 2022 | |
| Abbott Laboratories | $12.91 | 2021 | |
| Astellas Pharma US INC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.